LIN FY2025 SEC EDGAR DEF 14A #2 of 168 in industry

Linde PLC CEO pay ratio

The CEO earned $21.8M in FY2025 against median worker pay of $50,860 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
L2
Filing date
2026-04-29
Industry
Chemicals & Pharmaceuticals
Industry rank
#2/168

Data updated August 2026

Subscribe to Linde PLC CEO pay filing updates (RSS)

CEO-to-worker pay ratio
428:1
Extreme (Scale: 0–1000:1)
CEO pay
$21.8M
Median worker
$50,860

Answer first

Linde PLC's FY2025 CEO total of $21.8M ranks #148 of 1,423 complete filings; its 428:1 pay ratio ranks #123. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $50,860. Industry placement uses the FY2025 SIC-28 peer cohort (# 2 of 168, 99th percentile - top 1% of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#148
$21.8M of 1,423 FY2025
Ratio rank
#123
428:1 of 1,423
Industry pct
99th
top 1% of industry peers by pay ratio

How Linde PLC ranks nationally

Linde PLC CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$21,777,870 Top 10% higher than 90% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). Below this entry. $17,500,000–$20,000,000: 54 companies (4%). Below this entry. $20,000,000–$22,500,000: 24 companies (2%). This entry sits in this band. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Linde PLC vs. Chemicals & Pharmaceuticals peers

CEO total pay ($21.8M) against pay ratio (428:1) for Linde PLC (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both5924457.816787382.627650307.538513232.449376157.322.3:1130.4:1238.5:1346.6:1454.6:1CEO total payPay ratio (CEO : median worker)Linde PLC, CEO total pay: 21777870 · Pay ratio (CEO : median worker): 428:1Linde PLCKeenova Therapeutics plc, CEO total pay: 47401080 · Pay ratio (CEO : median worker): 435:1Keenova Therapeutics plcBausch Health Companies Inc., CEO total pay: 16877326 · Pay ratio (CEO : median worker): 401:1Bausch Health Companies Inc.Ppg Industries Inc, CEO total pay: 16555264 · Pay ratio (CEO : median worker): 352:1Ppg Industries IncViatris Inc, CEO total pay: 15280383 · Pay ratio (CEO : median worker): 327:1Viatris IncELI LILLY & Co, CEO total pay: 36698337 · Pay ratio (CEO : median worker): 293:1ELI LILLY & Co
Linde PLC vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Linde PLC's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Linde PLC

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
428:1
FY2025
vs prior FY
+37:1
from FY2024 391:1
CEO $ YoY
+5.2%
$21.8M latest
Filings shown
5
FY2021–2025
Linde PLC CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $31.4M - $40,659 773:1 -
2022 $14.9M -53% $45,654 326:1 -447:1
2023 $19.2M +29% $49,230 390:1 +64:1
2024 $20.7M +7.8% $52,889 391:1 +1:1
2025 $21.8M +5.2% $50,860 428:1 +37:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1707925, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
428:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$21.8M
Companies in Industry
168
vs. Industry Median
Above
#2 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Linde PLC: HIGH · PEAK pay ratio

Linde PLC's FY2025 ratio 428:1 ranks #2 of 168 Chemicals & Pharmaceuticals filers (99th percentile). the CEO earned 428× the median employee ($50,860) in FY2025.

Median employee $50,860 (PAR-MED); HIGH · PEAK stamps put about 428 median-wage years per CEO year.

CEO Total Pay

$21.8M

FY2025 Summary Compensation, well above median

Pay Ratio

428:1

Outlier, top decile

Linde PLC in the higher Chemicals & Pharmaceuticals third

Linde PLC's FY2025 ratio 428:1 ranks #2 of 168 Chemicals & Pharmaceuticals filers (99th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Linde PLC's $21.8M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #148 and ratio rank #123 split - treat 428:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$21.8M
Median Employee Pay
$50,860
Pay Ratio
428:1
Filing Date
2026-04-29

Company Info

Ticker
LIN
CIK
1707925
Industry
Chemicals & Pharmaceuticals
SIC Code
2810
State
L2
View SEC filings →
SEC EDGAR DEF 14A for CIK 1707925, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Linde PLC's FY2025 ratio 428:1 ranks #2 of 168 Chemicals & Pharmaceuticals filers (99th percentile).

Read with Linde PLC

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps HIGH · PEAK · PAR-MED.

Kyndryl Holdings, Inc. · PEAK

ABS(ceo_total_comp) peer at $21.8M (Δ $12K lighter vs Linde PLC); EXTREME · PAR-MED vs this page's HIGH · PEAK · PAR-MED.
Nrg Energy, Inc. · PEAK

ABS(ceo_total_comp) peer at $21.8M (Δ $22K heavier vs Linde PLC); STEEP · HIGH-MED vs this page's HIGH · PEAK · PAR-MED.
Bristol Myers Squibb Co · PEAK

ABS(ceo_total_comp) peer at $21.9M (Δ $124K heavier vs Linde PLC); MID · ELITE-MED vs this page's HIGH · PEAK · PAR-MED.
Biomarin Pharmaceutical Inc · PEAK

ABS(ceo_total_comp) peer at $21.9M (Δ $150K heavier vs Linde PLC); MID · ELITE-MED vs this page's HIGH · PEAK · PAR-MED.
Keenova Therapeutics plc (SIC 28 pole)

Keenova Therapeutics plc stamps HIGH · OUTLIER nearest in-SIC by ABS(pay_ratio) to Linde PLC's HIGH filing.
National dual ranks · #148/#123

Linde PLC's FY2025 package sits #148 by CEO dollars and #123 by ratio under PEAK · HIGH.
Comp structure · PEAK

Linde PLC's PEAK CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Linde PLC (CIK 1707925), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.